Drug Candidates in Development
Focusing on chronic neuro-inflammatory conditions, Pilz Bioscience is developing a robust, diversified pipeline in multiple indications with high unmet medical needs. The initial target indication is Autism Spectrum Disorder (ASD).
Pilz is developing a unique combination of psychedelic molecules that delivers the full-spectrum biological effect and improved clinical outcomes.
Pilz is establishing a framework for personalized healthcare based on behavioral indicators alongside clinical biomarkers, guided by specialized professionals.
“What we’re understanding now is that regardless of receptor-level pharmacology, the really interesting changes that occur with [psychedelics] are in brain network dynamics— the way different areas of the brain communicate with each other.”